NDA 021476 · Waylis Therap
Lunesta
Eszopiclone · Oral
NovelLast checked: Nov 20, 2026Latest source record: Aug 18, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Dec 15, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
71
17 Phase 3, 5 recruiting
FAERS reports
25,514
10,237 serious, 1,692 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of LUNESTA. Some of these events may result in serious injuries, including death. Discontinue LUNESTA immediately if a patient experiences a complex sleep behavior [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning . Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of LUNESTA. Some of these events may result in serious injuries, including death. Discontinue LUNESTA immediately if a patient experiences a complex sleep behavior ( 4 , 5.1 ).
What it is approved for
From the label in effect Jan 8, 2025.
LUNESTA ® (eszopiclone) is indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, LUNESTA administered at bedtime decreased sleep latency and improved sleep maintenance. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only). LUNESTA is indicated for the treatment of insomnia. LUNESTA has been shown to decrease sleep latency and improve sleep maintenance ( 1 )
Mechanism: The mechanism of action of eszopiclone as a hypnotic is unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 2012 Supplement 26 · Efficacy · priority review Pediatric Written RequestPediatric Amendment 1Pediatric Medical Review
- Dec 15, 2004 Original approval · Type 1 - New Molecular Entity NovelReviewMedication GuideOther Important Information from FDA
3 products under this application
- LUNESTA · ESZOPICLONE 2MG · TABLET, ORAL · Prescription · TE AB
- LUNESTA · ESZOPICLONE 3MG · TABLET, ORAL · Prescription · TE AB
- LUNESTA · ESZOPICLONE 1MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Eszopiclone" as an intervention, any sponsor and status, largest first.
- 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary InsomniaPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00352144 · 830 participants · Start Oct 2003 · Primary completion Oct 2004
Drug: Eszopiclone; Placebo · For: Primary Insomnia
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 58 sites in all
- Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With InsomniaPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01710631 · 791 participants · Start Feb 2001 · Primary completion Aug 2002
Drug: eszopiclone 3 mg; placebo · For: Primary Insomnia
- A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and InsomniaPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00435279 · 678 participants · Start Jun 2007 · Primary completion Jul 2009
Drug: Eszopiclone; Placebo and 1 more · For: Major Depressive Disorder; Insomnia
Sites: Salzburg, Austria; Vienna, Austria; Split, Croatia · 69 sites in all
- National Adaptive Trial for PTSD Related InsomniaPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT03668041 · 673 participants · Start Feb 25, 2021 · Primary completion Mar 30, 2026
Drug: Trazodone; Eszopiclone · For: Insomnia
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Phoenix, Arizona · 35 sites in all
- A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive DisorderPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00368030 · 545 participants · Start Jan 2004 · Primary completion Oct 2004
Drug: Eszopiclone · For: Insomnia; Depressive Disorder, Major
Sites: Birmingham, Alabama; Peoria, Arizona; Tucson, Arizona · 65 sites in all
- Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated InsomniaPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00856973 · 486 participants · Start May 2009 · Primary completion Jul 2011
Drug: eszopiclone; eszopiclone and 1 more · For: Insomnia; Attention Deficit Hyperactivity Disorder
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 73 sites in all
- Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD SubjectsPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00616655 · 456 participants · Start Jan 2008 · Primary completion Dec 2008
Drug: eszopiclone; eszopiclone and 1 more · For: Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Arcadia, California; Beverly Hills, California · 57 sites in all
- Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety DisorderPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00235508 · 420 participants · Start Jun 2005 · Primary completion Apr 2006
Drug: Eszopiclone (Lunesta) · For: Insomnia; Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Mesa, Arizona; Scottsdale, Arizona · 64 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,890
- insomnia3,913
- dysgeusia3,855
- nausea1,428
- fatigue1,239
- middle insomnia1,217
- headache1,193
- dizziness899
- somnolence895
- anxiety868
- initial insomnia857
- pain835
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2,348 |
| 2006 | 4,423 |
| 2007 | 2,929 |
| 2008 | 481 |
| 2009 | 527 |
| 2010 | 726 |
| 2011 | 547 |
| 2012 | 718 |
| 2013 | 654 |
| 2014 | 659 |
| 2015 | 1,010 |
| 2016 | 1,374 |
| 2017 | 1,123 |
| 2018 | 1,232 |
| 2019 | 1,148 |
| 2020 | 1,041 |
| 2021 | 782 |
| 2022 | 823 |
| 2023 | 737 |
| 2024 | 827 |
| 2025 | 821 |
| 2026 | 584 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lunesta (Eszopiclone)
2024 spending
$5.9M
Beneficiaries
963
5,408 claims
Per beneficiary
$6,172
$28.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,718,493 |
| 2021 | $5,534,030 |
| 2022 | $4,925,760 |
| 2023 | $5,915,290 |
| 2024 | $5,944,116 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis.
Yue JL, Chang XW, Zheng JW, et al. · Sleep Med Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
McElroy H, O'Leary B, Adena M, et al. · J Manag Care Spec Pharm 2021 · Comparative Study, Network Meta-Analysis
- Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: A systematic review and meta-analysis of double-blind randomized controlled trials.
Maruki T, Takeshima M, Yoshizawa K, et al. · Psychiatry Clin Neurosci 2025 · Systematic Review, Meta-Analysis
- Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management.
Stelzer FG, Bacelar A, Éckeli AL, et al. · Arq Neuropsiquiatr 2025 · Practice Guideline, Systematic Review
- Eszopiclone for insomnia.
Rösner S, Englbrecht C, Wehrle R, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Waylis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.